Mobile

A PHASE 2A, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE DOSE, 5-WAY CROSSOVER STUDY ASSESSING THE PHARMACODYNAMIC, PHARMACOKINETIC AND SAFETY PROFILES OF ORAL INHALED PF-03635659 IN PATIENTS WITH MODERAT...

Update Il y a 4 ans
Reference: EUCTR2009-014540-11

A PHASE 2A, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE DOSE, 5-WAY CROSSOVER STUDY ASSESSING THE PHARMACODYNAMIC, PHARMACOKINETIC AND SAFETY PROFILES OF ORAL INHALED PF-03635659 IN PATIENTS WITH MODERATE CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To estimate the bronchodilatory trough effect of 3 single dose levels of PF-03635659 delivered via the CRC749 inhaler device in moderate COPD subjects in order to select the lowest efficacious dose to study in Phase 2b. To investigate the pharmacokinetics of 3 single dose levels of PF-03635659 delivered via the CRC749 inhaler device in moderate COPD subjects.

Inclusion criteria

  • Chronic Obstructive Pulmonary Disease (COPD)

Links